Industry News for MS
Find the latest news and headlines on new drug discoveries, healthcare research, and development.
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is [...]
Press Release: New 48-Week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a [...]
The Siegel Rare Neuroimmune Association Marks 30 Years of Improving Quality of Life for People With Rare Neuroimmune Disorders
Not-for-profit celebrates past achievements and looks to the future POWELL, Ohio, February 29, 2024 (Newswire.com) - The Siegel Rare [...]
The Language of MS: How Much Does It Matter?
I got an email recently from someone well up the chain of command at a multiple sclerosis (MS) patient advocacy organization. The purpose [...]
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
Phase III OCARINA II trial met primary and secondary endpoints Ocrevus 10-minute injection has the potential to further improve the [...]
Helius launches UpScript telehealth e-commerce site
PDF Version New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 [...]
Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023
Eligible patients will receive full MS patient support program through Cycle Vita™ Boston, Massachusetts and San Jose, California – [...]
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Janssen Pharmaceuticals U.S. transparency report
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Genentech premiers #MSVisibility 2022
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Sanofi’s 2022 annual pricing principles report
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
New preclinical tolebrutinib data demonstrated superior brain penetration and potency
Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain [...]
Study: Epstein-Barr virus can cause multiple sclerosis
Researchers from Harvard University recently found that the Epstein-Barr virus (EBV), which is most known for leading to mononucleosis, is [...]
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ET on an [...]
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
#MSVisibility virtual concert: recording now available
#MSVisibility Virtual Concert Thank you for your interest in the first-ever #MSVisibility Virtual Concert, a free event to celebrate and [...]
Phase 1/2 study to evaluate the safety and efficacy of ATA188 in progressive multiple sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the [...]
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
Dr. Thrower discusses management, different types of multiple sclerosis fatigue
https://youtu.be/vtwauNrp8Jo Ben Thrower, MD, Medical Director, Andrew C. Carlos Multiple Sclerosis Institute, talks about different [...]
New data further reinforce Genentech’s Ocrevus (ocrelizumab) as effective treatment
7 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Inebilizumab approved for treatment of Neuromyelitis Optica Spectrum Disorder
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]
Avonex and Plegridy label updates
The Plegridy (peginterferon beta-1a) Prescribing Information and the Avonex (interferon beta-1a) Prescribing Information was updated in the [...]
FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis
The U.S. Food and Drug Administration (FDA) has approved Zeposia (ozanimod) oral capsules to treat adults with relapsing forms [...]
MedDay report top-line data from trial “SPI2” for treatment of progressive forms of multiple sclerosis
Paris, France, March 10, 2020 – MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of its [...]
Brain activity patterns linked with improved learning and memory in multiple sclerosis
A recent article by Kessler Foundation researchers demonstrated g people with multiple sclerosis (MS). The article, "Brain activation [...]
Robotic ‘trousers’ could help thousands of multiple sclerosis sufferers stand and walk again
Robotic ‘trousers’ could help thousands of people left unable to stand or walk due to multiple sclerosis find their feet again. The [...]
Use of DMTs changing ‘natural history’ of relapsing multiple sclerosis, study says
People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of [...]
